Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone.
The Pharma Data
SEPTEMBER 1, 2021
Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Global Therapeutic Area Head, Neuroscience, Janssen Research & Development, LLC.
Let's personalize your content